Jonathan Allan Sells 2,861 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Posted by George Bondi on Aug 20th, 2026

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) General Counsel Jonathan Allan sold 2,861 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $91,637.83. Following the completion of the transaction, the general counsel owned 21,225 shares in the company, valued at approximately $679,836.75. This trade represents a 11.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jonathan Allan also recently made the following trade(s):

On Tuesday, June 16th, Jonathan Allan sold 1,457 shares of Stoke Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $43,637.15.

Stoke Therapeutics Stock Performance

STOK opened at $33.03 on Thursday. The firm has a 50 day moving average price of $30.90 and a 200 day moving average price of $32.23. The company has a market cap of $2.13 billion, a PE ratio of -9.89 and a beta of 1.20. Stoke Therapeutics, Inc. has a 1 year low of $18.00 and a 1 year high of $40.22.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million during the quarter, compared to analysts’ expectations of $4.89 million. On average, sell-side analysts predict that Stoke Therapeutics, Inc. will post -3.5 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new stake in shares of Stoke Therapeutics in the 2nd quarter worth about $192,307,000. RTW Investments LP grew its stake in Stoke Therapeutics by 8.3% in the fourth quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock worth $176,057,000 after purchasing an additional 423,331 shares in the last quarter. Redmile Group LLC grew its stake in Stoke Therapeutics by 3.2% in the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock worth $135,584,000 after purchasing an additional 130,050 shares in the last quarter. Morgan Stanley increased its holdings in Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock valued at $112,555,000 after buying an additional 9,108 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in Stoke Therapeutics by 13.7% in the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after buying an additional 423,601 shares during the last quarter.

Analyst Ratings Changes

Several equities analysts recently weighed in on STOK shares. Weiss Ratings restated a “sell (d)” rating on shares of Stoke Therapeutics in a report on Friday, August 7th. The Goldman Sachs Group started coverage on Stoke Therapeutics in a research report on Monday, July 13th. They issued a “buy” rating and a $44.00 price objective on the stock. Canaccord Genuity Group reduced their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Chardan Capital reiterated a “buy” rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. Finally, BTIG Research reiterated a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a report on Monday, May 11th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Get Our Latest Analysis on Stoke Therapeutics

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.